Sign In
test

Christopher Martin Meekins

Jones Hill Capital Lp

Assets Managed
$466.471M
Holdings
26
Last Quarter
2026 - Q1
Filed Date
1mo 14d ago
Growth Rate
0%(2Q avg: 0%)
Sustained Growth
0 quarters

Portfolio positions

This chart displays the top 10 holdings in Jones Hill Capital Lp's 2026 - Q1 portfolio, based on their 13F SEC filing, out of a total of 26 positions.

Assets under management

The assets under management (AUM) of Jones Hill Capital Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 0 quarters. As of the latest 13F SEC filing for 2026 - Q1, they manage 466.471M in assets, with a quarterly growth rate of 0% and a 2-quarter average growth rate of 0%. The portfolio is managed by Christopher Martin Meekins, and others.

Portfolio holdings

InvestmentPortfolio %Reported Value
BMRN
Biomarin Pharmaceutical Inc
Recent Activity
New Position
15.37%
$71.651M
1.268M shares@ $56.49 avg price
VRTX
Vertex Pharmaceuticals Inc
Recent Activity
New Position
10.4%
$48.496M
108,603 shares@ $446.55 avg price
PCVX
Vaxcyte Inc
Recent Activity
New Position
8.04%
$37.471M
644,831 shares@ $58.11 avg price
NUVL
Nuvalent Inc-a
Recent Activity
New Position
6.61%
$30.82M
300,830 shares@ $102.46 avg price
CAPR
Capricor Therapeutics Inc
Recent Activity
New Position
5.93%
$27.64M
909,207 shares@ $30.41 avg price
TERN
Terns Pharmaceuticals Inc
Recent Activity
New Position
5.9%
$27.48M
521,237 shares@ $52.73 avg price
BCAX
Bicara Therapeutics Inc
Recent Activity
New Position
5.38%
$25.064M
1.26M shares@ $19.89 avg price
ANIP
Ani Pharmaceuticals Inc
Recent Activity
New Position
5.26%
$24.5M
318,591 shares@ $76.91 avg price
RARE
Ultragenyx Pharmaceutical In
Recent Activity
New Position
5.24%
$24.418M
1.166M shares@ $20.95 avg price
ELVN
Enliven Therapeutics Inc
Recent Activity
New Position
4.99%
$23.247M
593,040 shares@ $39.2 avg price

1-10 of 26